Announcing the release of the NFX Original film THE FUTURE OF LONGEVITY: The Battle Against Human Aging.

Many thanks and Gratitude to Omri Amirav-Drory and Eric Ward at NFX for creating this documentary featuring scientists making a difference in the field of longevity. We are honored they chose to include Cyclarity Therapeutics ‘ CEO, Scientific Affairs, Matthew “Oki” O’Connor, Head of Scientific Computing, Amelia Anderson and Vice President of Biology, Daniel Clemens.

Based at the Buck Institute for Research on Aging in Novato, California, US, we are working to reverse atherosclerosis. Our mission to provide a drug (UDP-003) that can genuinely modify the course of primary coronary heart disease, peripheral artery disease, and carotid stenosis.

The drug is clinic-ready (in vials and labeled, and the safety package is being finalized). We expect phase 1 to be performed in Australia under the direction of the Victoria Heart Institute in 2024, with a multi-country, multi-site phase 2 in ’25 through ‘27. The company is currently raising a Series A-1 to fund the phase 1 trial.

About Cyclarity Therapeutics, Inc.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com